Together, these results demonstrated that co-activation of GR and ERα induced robust differentiation in combination with decreased angiogenesis and tumor burden in vivo, highlighting the potential of triggering both receptors as a putative therapeutic approach. The gene discussed is NR3C1; the disease is neoplasm.